Primary Prevention of Sudden Death in Post-Infarction Patients: When ICD Implantation is Really Cost-effective

  • S. C. Hammill
Conference paper


The implantable cardioverter defibrillator (ICD) has been convincingly demonstrated to reduce mortality in randomized clinical trials that have assessed this treatment strategy for both primary and secondary prevention of sudden cardiac death [1–6]. This important advance in therapy has the potential to reduce the risk of sudden cardiac death which now affects over 400,000 persons in the United States each year. The estimated number of ICD implantations for 2003 is expected to exceed 100,000 worldwide.


Sudden Cardiac Death Implantable Cardioverter Defibrillator Implantable Cardioverter Defibrillator Therapy Implantable Cardioverter Defibrillator Implantation Secondary Prevention Trial 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    AVID-Investigators (1997) A comparison of antiarrhythmic drug therapy with implantable defibrillator in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics Versus Implantable Defibrillators (AVID) investigators. N EnglJMed 337:1576–1583CrossRefGoogle Scholar
  2. 2.
    Connolly SJ, Gent M, Roberts RS et al (2000) Canadian Implantable Defibrillator Study (CIDS): a randomized trial of the implantable cardioverter-defibrillator against amiodarone. Circulation 101:1297–1302PubMedCrossRefGoogle Scholar
  3. 3.
    Kuck KH, Cappato R, Siebels J, Ruppel R (2000) Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: The Cardiac Arrest Study Group (CASH). Circulation 102(7):748–754Google Scholar
  4. 4.
    Moss AJ, Hall J, Cannom DS et al (1996) Improved survival with an implantable cardioverter-defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter automatic defibrillator implantation trial investigators. N Engl J Med 335(26):1933–1940PubMedCrossRefGoogle Scholar
  5. 5.
    Moss AJ, Zareba W, Hall WJ et al (2002) Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346:877–883PubMedCrossRefGoogle Scholar
  6. 6.
    Buxton AE, Lee K, Fisher JD et al (1999) A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter unsustained tachycardia trial investigators. N Engl J Med 341:1882–1890PubMedCrossRefGoogle Scholar
  7. 7.
    Pfeffer MA, Braunwald E, Moye LA et al (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE investigators. N Engl Med 327:669–677CrossRefGoogle Scholar
  8. 8.
    SOLVD-Investigators (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD-Investigators. N Engl J Med 325:293–302CrossRefGoogle Scholar
  9. 9.
    CIBIS-Investigators (1999) The cardiac insufficiency bisprolol study II (CIBIS-II): a randomized trial. Lancet 353:9–13CrossRefGoogle Scholar
  10. 10.
    ISIS-2 Collaborative Group (1988) Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among ISIS-2 (Second international study of infarct survival). Lancet 2:349–360Google Scholar
  11. 11.
    Merit-HF Study Group (1999) Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet 353:2001–2007CrossRefGoogle Scholar
  12. 12.
    4 S Investigators (1994) Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: Scandinavian Simvastain Survival Study (4S). Lancet 344:1383–1389Google Scholar
  13. 13.
    Seidl K, Senges J (2003) Worldwide utilization of implantable cardioverter-defibrilla-tor now and in the future. Cardiac Electrophysiology Review, In PressGoogle Scholar
  14. 14.
    Essebag V, Eisenberg MJ (2003) Expanding indications for defibrillators after myo-cardial infarction: risk stratification and cost effectiveness. Cardiac Electrophysiology Review (in press) Google Scholar
  15. 15.
    Bigger JT (2002) Expanding indications for implantable cardiac defibrillators. N Engl J Med 346:931–933PubMedCrossRefGoogle Scholar
  16. 16.
    Sanders GD, Hlatky MA, Every NR et al (2001) Potential cost effectiveness of prophylactic use of the implantable cardioverter-defibrillator after myocardial infarction. Ann Int Med 135:870–883PubMedGoogle Scholar
  17. 17.
    Larsen G, Hallstrom A, McAnulty J et al (2002) Cost-effectiveness of the implantable cardioverter-defibrillator versus antiarrhythmic drugs in survivors of serious ventricular tachyarrhythmias. Circulation 105:2049–2057PubMedCrossRefGoogle Scholar
  18. 18.
    Sheldon R, O’Brien BJ, Blackhouse G et al (2001) Effect of clinical risk stratification on cost-effectiveness of the implantable cardioverter-defibrillator: the Canadian implantable defibrillator study. Circulation 104(14):1622–1626PubMedCrossRefGoogle Scholar
  19. 19.
    Domanski MJ, Sakseena S, Epstein A et al (1999) Relative effectiveness of the implantable cardioverter-defibrillator and antiarrhythmic drugs in patients with varying degrees of left ventricular dysfunction who have survived malignant ventricular arrhythmias. J Am Coll Cardiol 34:1090–1095PubMedCrossRefGoogle Scholar
  20. 20.
    Boriani G, Biffi M, Martignani A et al (2001) Cost-effectiveness of implantable cardio-verter-defibrillators. Euro Hrt J 22:990–996CrossRefGoogle Scholar
  21. 21.
    Hlatiky MA, Bigger T (2001) Cost-effectiveness of the implantable cardioverter-defibrillator. Lancet 357:1817–1818CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2004

Authors and Affiliations

  • S. C. Hammill
    • 1
  1. 1.Department of Internal Medicine, Cardiovascular DivisionMayo ClinicRochesterUSA

Personalised recommendations